We used additional expression data derived from different breast cancer gene array cohorts, and we tested if the SNAT2 levels correlated with worse outcomes in ER+ patients treated with all adjuvant endocrine treatments (including aromatase inhibitors) or tamoxifen only. This evidence concerns the gene SLC38A2 and breast cancer.